Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: VIATRIS INC · Firm: VIATRIS INC.
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars S. 1416, Affordable Prescriptions for Patients Act Senate HELP Committee Lower Health Care Costs Act of 2019 FY 2020 House/Senate Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2019 · second_quarter · Q2
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars S. 1416, Affordable Prescriptions for Patients Act Senate HELP Committee Lower Health Care Costs Act of 2019 FY 2020 House/Senate Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering
Source: Senate LDA
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 CY2020 CMS Call Letter
Further Extension of Continuing Appropriations Act, 2021
Client: VIATRIS INC · Firm: VIATRIS INC.
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars S. 1416, Affordable Prescriptions for Patients Act Senate HELP Committee Lower Health Care Costs Act of 2019 FY 2020 House/Senate Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering
Further Extension of Continuing Appropriations Act, 2021
Client: VIATRIS INC · Firm: VIATRIS INC.
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 CY2020 CMS Call Letter
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 CY2020 CMS Call Letter
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars S. 1416, Affordable Prescriptions for Patients Act Senate HELP Committee Lower Health Care Costs Act of 2019 FY 2020 House/Senate Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars S. 1416, Affordable Prescriptions for Patients Act Senate HELP Committee Lower Health Care Costs Act of 2019 FY 2020 House/Senate Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 CY2020 CMS Call Letter
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 CY2020 CMS Call Letter
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars S. 1416, Affordable Prescriptions for Patients Act Senate HELP Committee Lower Health Care Costs Act of 2019 FY 2020 House/Senate Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars S. 1416, Affordable Prescriptions for Patients Act Senate HELP Committee Lower Health Care Costs Act of 2019 FY 2020 House/Senate Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: VIATRIS INC · Firm: VIATRIS INC.
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 CY2020 CMS Call Letter
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: VIATRIS INC · Firm: VIATRIS INC.
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars S. 1416, Affordable Prescriptions for Patients Act Senate HELP Committee Lower Health Care Costs Act of 2019 FY 2020 House/Senate Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: VIATRIS INC · Firm: VIATRIS INC.
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: VIATRIS INC · Firm: VIATRIS INC.
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars
Trade issues related to generic medicines
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
2019 · first_quarter · Q1
Trade issues related to generic medicines
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars H.R. 938 - BLOCKING Act of 2019 H.R. 1520 - The Purple Book Continuity Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 CY2020 CMS Call Letter
Tariff issues related to generic medicines
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
2018 · fourth_quarter · Q4
Trade issues related to generic medicines
Tariff issues related to generic medicines
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, White House Office
2018 · third_quarter · Q3
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars
Trade issues related to generic medicines
Tariff issues related to generic medicines
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, White House Office